Indications for: TOBI Podhaler
Management of cystic fibrosis patients with P. aeruginosa.
Adults and Children:
<6yrs: not established. For oral inhalation use only with Podhaler device; do not swallow caps. Give in alternate 28-day cycles (28 days on, 28 days off). ≥6yrs: Inhale contents of 4 caps twice daily, as close to every 12hrs as possible (must be at least 6hrs apart). Give last when using multiple inhalation therapies.
TOBI Podhaler Warnings/Precautions:
Safety and efficacy have not been demonstrated in patients <6yrs, in those with FEV1 <25% or >80% predicted, or patients colonized with B. cepacia. Known or suspected auditory, vestibular, renal, or neuromuscular dysfunction. Myasthenia gravis. Parkinson’s disease. Consider performing an audiogram at baseline (esp. at risk of auditory dysfunction). Monitor serum tobramycin levels in auditory or renal dysfunction patients, or if concomitant other IV aminoglycosides (or other nephrotoxic or ototoxic drugs) as needed. Monitor renal function as needed. Elderly. Embryo-fetal toxicity. Pregnancy. Nursing mothers: monitor infants.
TOBI Podhaler Classification:
TOBI Podhaler Interactions:
Concomitant ethacrynic acid, furosemide, urea, IV mannitol: not recommended. Diuretics may increase toxicity. Avoid concomitant and/or sequential use with other neurotoxic, nephrotoxic, or ototoxic drugs.
Cough, lung disorder, productive cough, dyspnea, pyrexia, oropharyngeal pain, dysphonia, hemoptysis, headache; hearing loss, tinnitus, nephrotoxicity, bronchospasm.
Caps—8, 56, 224 (w. Podhaler device)